SG10201407012XA - Kinase inhibitors - Google Patents
Kinase inhibitorsInfo
- Publication number
- SG10201407012XA SG10201407012XA SG10201407012XA SG10201407012XA SG10201407012XA SG 10201407012X A SG10201407012X A SG 10201407012XA SG 10201407012X A SG10201407012X A SG 10201407012XA SG 10201407012X A SG10201407012X A SG 10201407012XA SG 10201407012X A SG10201407012X A SG 10201407012XA
- Authority
- SG
- Singapore
- Prior art keywords
- kinase inhibitors
- kinase
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25622209P | 2009-10-29 | 2009-10-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201407012XA true SG10201407012XA (en) | 2014-11-27 |
Family
ID=43922599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201407012XA SG10201407012XA (en) | 2009-10-29 | 2010-10-29 | Kinase inhibitors |
Country Status (18)
Country | Link |
---|---|
US (1) | US8404677B2 (en) |
EP (1) | EP2493313B1 (en) |
JP (1) | JP5993742B2 (en) |
KR (1) | KR101690358B1 (en) |
CN (1) | CN102695416B (en) |
BR (1) | BR112012010085B1 (en) |
CA (1) | CA2779105C (en) |
CL (1) | CL2012001073A1 (en) |
EA (1) | EA029273B1 (en) |
ES (1) | ES2658290T3 (en) |
IL (1) | IL219447A (en) |
MX (1) | MX2012004846A (en) |
MY (1) | MY173494A (en) |
NZ (2) | NZ599040A (en) |
SG (1) | SG10201407012XA (en) |
TR (1) | TR201802464T4 (en) |
WO (1) | WO2011053861A1 (en) |
ZA (1) | ZA201203842B (en) |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201506591TA (en) | 2010-05-20 | 2015-09-29 | Array Biopharma Inc | Macrocyclic compounds as trk kinase inhibitors |
WO2012097479A1 (en) * | 2011-01-21 | 2012-07-26 | Abbott Laboratories | Bicyclic inhibitors of anaphastic lymphoma kinase |
CN103415516A (en) * | 2011-01-21 | 2013-11-27 | Abbvie公司 | Bicyclic inhibitors of ALK |
MX361458B (en) * | 2011-08-23 | 2018-12-06 | Asana Biosciences Llc | Pyrimido- pyridazinone compounds and use thereof. |
US9085578B2 (en) | 2012-02-20 | 2015-07-21 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
MX2014010176A (en) * | 2012-02-23 | 2014-11-10 | Abbvie Inc | Pyridopyrimidinone inhibitors of kinases. |
CA2868156C (en) * | 2012-03-22 | 2020-07-28 | Genosco | Substituted pyridopyrimidine compounds and their use as flt3 inhibitors |
AP3902A (en) | 2012-06-29 | 2016-11-17 | Pfizer | Novel 4-(substituted-amino)-7H-pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors |
WO2014023385A1 (en) * | 2012-08-07 | 2014-02-13 | Merck Patent Gmbh | Pyridopyrimidine derivatives as protein kinase inhibitors |
MX2015002006A (en) * | 2012-08-13 | 2015-06-02 | Novartis Ag | Bicyclic heteroaryl cycloalkyldiamine derivatives as inhibitors of spleen tyrosine kinases (syk). |
CN103664938A (en) * | 2012-09-12 | 2014-03-26 | 山东亨利医药科技有限责任公司 | Benzopyrimidine-containing SYK inhibitor |
CA2884921A1 (en) | 2012-09-18 | 2014-03-27 | Ziarco Pharma Ltd | 2-(2-aminocyclohexyl)amino-pyrimidine-5-carboxamides as spleen tyrosine kinasei(syk) inhibitors |
US9533986B2 (en) | 2012-09-27 | 2017-01-03 | Portola Pharmaceuticals, Inc. | Bicyclic dihydropyridone kinase inhibitors |
JP6437452B2 (en) | 2013-01-14 | 2018-12-12 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
HUE050215T2 (en) | 2013-01-15 | 2020-11-30 | Incyte Holdings Corp | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors |
CN104341437A (en) * | 2013-07-30 | 2015-02-11 | 山东亨利医药科技有限责任公司 | SYK inhibitor containing bicyclo-radical |
JP2016528298A (en) | 2013-08-23 | 2016-09-15 | インサイト・コーポレイションIncyte Corporation | Furopyridine and thienopyridinecarboxamide compounds useful as PIM kinase inhibitors |
EP3083618B1 (en) | 2013-12-17 | 2018-02-21 | Pfizer Inc | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
WO2015146928A1 (en) * | 2014-03-24 | 2015-10-01 | 武田薬品工業株式会社 | Heterocyclic compound |
WO2016007540A2 (en) | 2014-07-10 | 2016-01-14 | The J. David Gladstone Institutes | Compositions and methods for treating dengue virus infection |
US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
KR20160035411A (en) * | 2014-09-23 | 2016-03-31 | 주식회사 오스코텍 | Pyridopyrimidine derivatives as lrrk2 (leucine rich repeat kinase 2) inhinitor |
WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
KR101845931B1 (en) | 2015-06-18 | 2018-04-05 | 한국화학연구원 | Heteroaryl derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical composition for use in preventing or treating PI3 kinase related diseases |
WO2016204429A1 (en) * | 2015-06-18 | 2016-12-22 | 한국화학연구원 | Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient |
EA035049B1 (en) | 2015-07-16 | 2020-04-22 | Аррэй Байофарма Инк. | SUBSTITUTED PYRAZOLO[1,5-a]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS |
AR105967A1 (en) | 2015-09-09 | 2017-11-29 | Incyte Corp | SALTS OF A PIM QUINASA INHIBITOR |
WO2017046675A1 (en) | 2015-09-14 | 2017-03-23 | Pfizer Inc. | Novel imidazo [4,5-c] quinoline and imidazo [4,5-c][1,5] naphthyridine derivatives as lrrk2 inhibitors |
TW201718546A (en) | 2015-10-02 | 2017-06-01 | 英塞特公司 | Heterocyclic compounds useful as PIM kinase inhibitors |
AR106830A1 (en) * | 2015-12-04 | 2018-02-21 | Asana Biosciences Llc | USES OF PIRIDAZINONES TO TREAT CANCER |
TWI704148B (en) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
JOP20190077A1 (en) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
US11168090B2 (en) | 2017-01-18 | 2021-11-09 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors |
JOP20190213A1 (en) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | Macrocyclic compounds as ros1 kinase inhibitors |
CN107194205B (en) * | 2017-05-31 | 2020-11-24 | 浙江大学 | JAK2 kinase inhibitor with bactericidal activity and virtual screening method thereof |
TW202410896A (en) | 2017-10-10 | 2024-03-16 | 美商絡速藥業公司 | Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile |
TWI791053B (en) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof |
AR113922A1 (en) | 2017-12-08 | 2020-07-01 | Incyte Corp | LOW DOSE COMBINATION THERAPY FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS |
CN111372932B (en) | 2017-12-21 | 2023-11-21 | 勃林格殷格翰国际有限公司 | Novel benzylamino-substituted pyridopyrimidinones and derivatives as SOS1 inhibitors |
EP3728217B1 (en) * | 2017-12-22 | 2023-11-15 | HiberCell, Inc. | Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
TW201932464A (en) | 2018-01-18 | 2019-08-16 | 美商亞雷生物製藥股份有限公司 | Substituted pyrazolyl[4,3-C]pyridine compounds as RET kinase inhibitors |
EP3740491A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
WO2019143991A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS |
CN110066236B (en) * | 2018-01-24 | 2023-03-24 | 上海迪诺医药科技有限公司 | 1H-pyrrole derivative, preparation method thereof, pharmaceutical composition and application thereof |
JP7350005B2 (en) * | 2018-03-30 | 2023-09-25 | レ ラボラトワール セルヴィエ | Heterobicyclic inhibitors of MAT2A and methods of use for the treatment of cancer |
KR20190131981A (en) * | 2018-05-18 | 2019-11-27 | 재단법인 대구경북첨단의료산업진흥재단 | Pharmaceutical composition for use in preventing or treating Traumatic Brain Injury or stroke |
AU2019292207B2 (en) * | 2018-06-27 | 2022-06-30 | Oscotec Inc. | Pyridopyrimidinone derivatives for use as Axl inhibitors |
KR20200022712A (en) * | 2018-08-23 | 2020-03-04 | 주식회사 오스코텍 | Crystalline form of 8-bromo-2-(1-methylpiperidin-4-ylamino)-4-(4-phenoxyphenylamino)pyrido[4,3-d]pyrimidin-5(6h)-one hydrochloride and preparation method thereof |
JP2022500383A (en) | 2018-09-10 | 2022-01-04 | アレイ バイオファーマ インコーポレイテッド | Condensed heterocyclic compound as a RET kinase inhibitor |
CN111285882B (en) * | 2018-12-07 | 2022-12-02 | 四川科伦博泰生物医药股份有限公司 | Fused ring compound, pharmaceutical composition containing same, and preparation method and application thereof |
TW202110831A (en) * | 2019-06-04 | 2021-03-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | Pyridone derivatives, a preparation method thereof, and medical applications thereof |
TW202112784A (en) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | Chromenopyrimidine derivatives as phosphatidylinositol phosphate kinase inhibitors |
CN110327347B (en) * | 2019-08-16 | 2021-06-01 | 陕西科技大学 | Application of G-749 in preparing antifungal medicine |
WO2021201574A1 (en) * | 2020-03-31 | 2021-10-07 | 보령제약 주식회사 | Method for producing compound as pi3k inhibitor, and intermediate compound for production thereof |
CN113493453B (en) * | 2020-04-07 | 2023-06-16 | 江苏恒瑞医药股份有限公司 | Condensed aromatic ring derivative, preparation method and medical application thereof |
US11691971B2 (en) | 2020-06-19 | 2023-07-04 | Incyte Corporation | Naphthyridinone compounds as JAK2 V617F inhibitors |
US11753413B2 (en) | 2020-06-19 | 2023-09-12 | Incyte Corporation | Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors |
BR112022026937A2 (en) * | 2020-06-30 | 2023-01-24 | Boryung Corp | METHOD FOR PREPARING COMPOUND AS PI3K INHIBITORS AND INTERMEDIATE COMPOUND FOR PREPARING THE SAME |
CR20230057A (en) | 2020-07-02 | 2023-08-15 | Incyte Corp | Tricyclic urea compounds as jak2 v617f inhibitors |
US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
CA3211748A1 (en) | 2021-02-25 | 2022-09-01 | Incyte Corporation | Spirocyclic lactams as jak2 v617f inhibitors |
UY39662A (en) * | 2021-03-10 | 2022-09-30 | Blueprint Medicines Corp | EGFR INHIBITORS |
KR20230056824A (en) * | 2021-10-20 | 2023-04-28 | 전북대학교산학협력단 | PAK4 inhibitors and use thereof |
WO2023076404A1 (en) | 2021-10-27 | 2023-05-04 | Aria Pharmaceuticals, Inc. | Methods for treating systemic lupus erythematosus |
WO2024055879A1 (en) * | 2022-09-16 | 2024-03-21 | 四川科伦博泰生物医药股份有限公司 | Class of fused bicyclic compounds, method for preparing same, and use thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
EP0974584B1 (en) | 1997-02-21 | 2003-01-15 | Takeda Chemical Industries, Ltd. | Fused ring compounds, process for producing the same and use thereof |
EP1899370A4 (en) * | 2005-05-12 | 2009-11-11 | Cytopia Res Pty Ltd | A crystal structure and uses thereof |
US7593820B2 (en) | 2005-05-12 | 2009-09-22 | Cytopia Research Pty Ltd | Crystal structure of human Janus Kinase 2 (JAK2) and uses thereof |
JO2783B1 (en) * | 2005-09-30 | 2014-03-15 | نوفارتيس ايه جي | 2-Amino-7,8-Dihidro-6H-Pyrido(4,3-D)Pyrimidin-5-ones |
TW200938542A (en) | 2008-02-01 | 2009-09-16 | Irm Llc | Compounds and compositions as kinase inhibitors |
ES2432414T3 (en) * | 2008-08-12 | 2013-12-03 | Glaxosmithkline Llc | Chemical compounds |
-
2010
- 2010-10-29 CN CN201080049613.4A patent/CN102695416B/en active Active
- 2010-10-29 WO PCT/US2010/054853 patent/WO2011053861A1/en active Application Filing
- 2010-10-29 NZ NZ599040A patent/NZ599040A/en unknown
- 2010-10-29 MX MX2012004846A patent/MX2012004846A/en active IP Right Grant
- 2010-10-29 MY MYPI2012001886A patent/MY173494A/en unknown
- 2010-10-29 SG SG10201407012XA patent/SG10201407012XA/en unknown
- 2010-10-29 EP EP10827573.6A patent/EP2493313B1/en active Active
- 2010-10-29 BR BR112012010085A patent/BR112012010085B1/en active IP Right Grant
- 2010-10-29 CA CA2779105A patent/CA2779105C/en active Active
- 2010-10-29 US US12/916,368 patent/US8404677B2/en active Active
- 2010-10-29 NZ NZ630860A patent/NZ630860A/en unknown
- 2010-10-29 ES ES10827573.6T patent/ES2658290T3/en active Active
- 2010-10-29 EA EA201290237A patent/EA029273B1/en not_active IP Right Cessation
- 2010-10-29 KR KR1020127011750A patent/KR101690358B1/en active IP Right Grant
- 2010-10-29 TR TR2018/02464T patent/TR201802464T4/en unknown
- 2010-10-29 JP JP2012537147A patent/JP5993742B2/en active Active
-
2012
- 2012-04-26 CL CL2012001073A patent/CL2012001073A1/en unknown
- 2012-04-29 IL IL219447A patent/IL219447A/en active IP Right Grant
- 2012-05-25 ZA ZA2012/03842A patent/ZA201203842B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2493313A1 (en) | 2012-09-05 |
NZ630860A (en) | 2016-03-31 |
KR101690358B1 (en) | 2017-01-09 |
MY173494A (en) | 2020-01-29 |
KR20120140643A (en) | 2012-12-31 |
EP2493313B1 (en) | 2017-12-13 |
EA201290237A1 (en) | 2013-04-30 |
ZA201203842B (en) | 2013-01-30 |
ES2658290T3 (en) | 2018-03-09 |
CA2779105C (en) | 2016-08-16 |
EP2493313A4 (en) | 2013-05-15 |
WO2011053861A8 (en) | 2011-10-27 |
CN102695416B (en) | 2017-03-08 |
IL219447A (en) | 2016-12-29 |
US20110269739A1 (en) | 2011-11-03 |
TR201802464T4 (en) | 2018-03-21 |
MX2012004846A (en) | 2012-10-05 |
NZ599040A (en) | 2014-11-28 |
AU2010313240A1 (en) | 2012-04-19 |
WO2011053861A1 (en) | 2011-05-05 |
BR112012010085B1 (en) | 2020-02-04 |
EA029273B1 (en) | 2018-03-30 |
JP5993742B2 (en) | 2016-09-14 |
JP2013509438A (en) | 2013-03-14 |
BR112012010085A2 (en) | 2017-06-20 |
IL219447A0 (en) | 2012-06-28 |
CA2779105A1 (en) | 2011-05-05 |
US8404677B2 (en) | 2013-03-26 |
CN102695416A (en) | 2012-09-26 |
CL2012001073A1 (en) | 2012-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1179477A1 (en) | Kinase inhibitors | |
ZA201203842B (en) | Kinase inhibitors | |
HK1216426A1 (en) | Apoptosis signal-regulating kinase inhibitors | |
EP2558099A4 (en) | Kinase inhibitors | |
ZA201004942B (en) | Ptrrolopyrazine kinase inhibitors | |
IL220212A0 (en) | Aminopyrimidine kinase inhibitors | |
EP2406236A4 (en) | Rho kinase inhibitors | |
HRP20130787T1 (en) | Imidazopyridazinecarbonitriles useful as kinase inhibitors | |
ZA201108048B (en) | P38map kinase inhibitor | |
HRP20130698T1 (en) | Novel phenylpyrazinones as kinase inhibitors | |
EP2519517A4 (en) | Type ii raf kinase inhibitors | |
EP2552208A4 (en) | Imidazolyl-imidazoles as kinase inhibitors | |
EP2396004A4 (en) | Selective kinase inhibitors | |
EP2552214A4 (en) | Pyrazolyl-pyrimidines as kinase inhibitors | |
HK1156026A1 (en) | Pyrazolopyridine kinase inhibitors | |
EP2552211A4 (en) | Indazolyl-pyrimidines as kinase inhibitors | |
GB201009731D0 (en) | Kinase inhibitors | |
EP2515657A4 (en) | Tyrosine kinase inhibitors | |
ZA201205277B (en) | Sphingosine kinase inhibitors | |
ZA201205237B (en) | Sphingosine kinase inhibitors | |
EP2231152A4 (en) | Thienopyranones as kinase inhibitors | |
EP2480076A4 (en) | Imidothiazole kinase inhibitors | |
GB0901898D0 (en) | Dual calpain-ros inhibitors | |
GB0914726D0 (en) | Kinase inhibitors | |
GB0901900D0 (en) | Dual calpain-ros inhibitors |